Fundraise

China's Zhongke Borui raises $15M to scale brain-computer interface devices

What's the deal? Zhongke Borui (Beijing) TechnologyDealroom has a profile for this one. Try Dealroom →, a brain-science solutions provider, has raised US$13.8M (roughly $15 million) in a Series B extension. Houji CapitalDealroom has a profile for this one. Try Dealroom → and Muhua Sci-Tech backed the round, announced in November 2026.

What's the endgame? The company develops non-invasive brain-function monitoring devices built on a "brain-computer interface plus artificial intelligence" base. Its product lines target anaesthesiology, intensive care, stroke centres, and neurosurgery.

Why now? The raise follows a Series B of tens of millions of CNY in March, led by Sanze Venture Capital. New funds will go toward deepening its business footprint, hiring, product development, expanding production, and entering global markets.

What's the backstory? Founded in March 2017 and incubated at the Chinese Academy of Sciences' Institute of Automation, Zhongke Borui was co-founded by chief scientist Jiang Tianzi and chief executive officer Zhang Xin. It works with Chinese hospitals including Xuanwu Hospital and Tiantan Hospital to ground products in clinical needs such as perioperative monitoring and stroke rehabilitation.

The company says it has developed what it calls the world's only non-invasive whole-brain multichannel cerebral oxygen monitor. It holds eight domestic medical device registrations plus EU CE certification, and says its products reach more than 600 hospitals at home and abroad.

The signal: By tying brain-computer interface research to approved clinical hardware, Zhongke Borui is positioning itself as a domestic alternative to foreign high-end brain-function equipment — a bet that medical-grade applications, not concept demos, will drive the sector's next phase.

Read more: sohu.com

Image credit: Generated with Gemini

More top stories